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Autism Spectrum Disorder (ASD) demonstrates high heritability and familial clustering, yet the genetic causes remain only partially
understood as a result of extensive clinical and genomic heterogeneity. Whole-genome sequencing (WGS) shows promise as a tool
for identifying ASD risk genes as well as unreported mutations in known loci, but an assessment of its full utility in an ASD group
has not been performed. We used WGS to examine 32 families with ASD to detect de novo or rare inherited genetic variants predicted
to be deleterious (loss-of-function and damaging missense mutations). Among ASD probands, we identified deleterious de novo muta-
tions in six of 32 (19%) families and X-linked or autosomal inherited alterations in ten of 32 (31%) families (some had combinations of
mutations). The proportion of families identified with such putative mutations was larger than has been previously reported; this yield
was in part due to the comprehensive and uniform coverage afforded by WGS. Deleterious variants were found in four unrecognized,
nine known, and eight candidate ASD risk genes. Examples includeCAPRIN1 andAFF2 (both linked to FMR1, which is involved in fragile
X syndrome), VIP (involved in social-cognitive deficits), and other genes such as SCN2A and KCNQ2 (linked to epilepsy), NRXN1, and
CHD7, which causes ASD-associated CHARGE syndrome. Taken together, these results suggest that WGS and thorough bioinformatic
analyses for de novo and rare inherited mutations will improve the detection of genetic variants likely to be associated with ASD or
its accompanying clinical symptoms.Introduction
Autism spectrum disorder (ASD; MIM 209850) is a
lifelong developmental condition affecting one in 88
children and is considered one of today’s most urgent
public health challenges. ASD is characterized by atypical
development of social communication and by the
presence of repetitive behaviors and restricted interests;
onset occurs in early childhood. ASD is also often
accompanied by intellectual disability, anxiety, sleep
problems, seizures, and gastrointestinal or other medical
problems.1 Given that diagnosis relies on clinical obser-
vation, families often experience a ‘‘diagnostic odyssey’’1Department of Paediatrics and Neurobiology, Duke University School of Medi
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Individuals with ASDs are increasingly presenting for
clinical genetics evaluation, and 10% have an identifiable
genetic condition. Fragile X (MIM 300524) (~1%–2% of
ASD cases), Rett (MIM 312750) (~0.5%), microdeletion
and microduplication, Cowden (MIM 158350), Timothy
(MIM 601005), and other syndromes are occasionally diag-
nosed.2 A recent study identified more than 103 genes and
44 genomic loci with mutations among individuals with
some form of ASD.3 These genes have all been causally
implicated in intellectual disability, indicating that these
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genetic basis. A genetic overlap between ASD and epi-
lepsy,4 as well as between ASD and neuropsychiatric condi-
tions5, is also apparent in many cases.
Family studies indicate a significant genetic basis for
ASD. Clinically identifiable copy-number variations
(CNVs) in ~10% of ASD-affected individuals5 has led to
the recommendation that microarrays be considered a
"standard of care" test for any ASD diagnostic evalua-
tion.6 Curation of large-scale CNV and other genomic
data sets has produced an evidence-based collection of
more than 100 genes implicated in ASD risk and the risk
for related disorders (we refer to these as known ASD-
linked genes).3,7,8 The first beneficiaries of genetic tests
are young children, in whom formal diagnosis based on
early behavioral signs can be challenging but who benefit
most from earlier behavioral intervention. Understanding
the genetic causes of ASD in an individual also potentially
informs prognosis, medical management, and familial-
recurrence risk assessment, and it can potentially facilitate
drug-intervention trials through stratification based on
genetic-pathway profiles.1,9
As one approach to identify additional ASD risk genes,
researchers have used genome-wide sequencing of the cod-
ing regions (collectively, the exome) of human DNA to
search for de novo mutations.10–13 Reports from such pro-
jects have indicated (1) a 2- to 4-fold increase in de novo
nonsense variants among ASD individuals in comparison
to their unaffected siblings, (2) some unrecognized ASD
risk genes, and (3) the possibility that hundreds of genes
are involved in the ASD risk.14 However, other genomic
investigations have identified mutations in individuals
with ASD in nongenic segments of DNA15 and in noncod-
ing RNAs,16,17 and in these examples and others, inherited
risk variants for ASD are known.18,19 Individuals with mul-
tiple genetic risk factors7,20–22 for ASD and/or associated
medical conditions3 are also documented.
There has been significant progress in identifying unrec-
ognized ASD risk variants as each technology of increasing
resolution (cytogenetics, microarrays, exome sequencing)
has become available. Even so, when one combines all
of the data from these complementary approaches, the
picture remains incomplete: the etiological basis of about
20% of cases of ASD, at most, can be explained to date.5
High heritability estimates (37%–90%)23,24 and family
studies reconfirm strong genetic contributions18 and sug-
gest that more genetic variants remain to be discovered.
We therefore implemented WGS in an effort to capture
all classes of genetic variation in a single experiment and
potentially more fully describe the genetic architecture of
ASD. We developed an analysis plan to search for de
novo or rare inherited mutations in previously recognized,
as well as unrecognized, genes linked to ASD and for vari-
ants in genes that might not be specific to ASD (Figure 1).
For the latter group, the genes could be related to core
autism symptoms, such as social communication, or con-
ditions strongly associated with ASD, such as intellectual
disability, seizures, or other medical complications. Given250 The American Journal of Human Genetics 93, 249–263, August 8that this is a pilot study for WGS in ASD and is based on
a relatively small number of families, we stress the need
for replication of our findings. However, promising results
thus far indicate that WGS could eventually help direct
personalized approaches to clinical management in indi-
viduals and families affected by ASD.Material and Methods
Samples for ASD-Affected Families
Thirty-two unrelated Canadian individuals with ASD (25 males
and seven females) were diagnosed with the Autism Diagnostic
Interview-Revised and the Autism Diagnostic Observation
Schedule-Generic protocols, and their family members were stud-
ied. They were selected from a cohort of ASD families with at least
one unaffected sibling at the time of the proband’s diagnosis, 25
and selection was based on available blood genomic DNA and
completeness of phenotype information. The samples were also
part of the Autism Genetic Resource Exchange (AGRE). We
obtained informed consent, as approved by the research ethics
boards at The Hospital for Sick Children andMcMaster University.
We assessed ASD probands with standardized measures of intelli-
gence, language, and adaptive function and collected information
on developmental, medical, and physical measures and family
history. Out of the 30 families for which we assessed IQ, there
were six probands with intellectual disability (IQ < 70). We geno-
typed all probands on high-resolution microarray platforms to
rule out obvious pathogenic CNVs26 (Figure S1 in the Supple-
mental Data available online).
Sequencing and Variant Discovery
Genomic DNA of probands and parents (trios) was extracted from
blood and sequenced with Hiseq2000 technology (Illumina). DNA
was extracted and sheared into fragments, which were then puri-
fied by gel electrophoresis. DNA fragments were ligated with
adaptor oligonucleotides to form paired-end DNA libraries with
an insert size of 500 bp. To enrich libraries for sequences with 50
and 30 adaptors, we used ligation-mediated PCR amplification
with primers complimentary to the adaptor sequences. The DNA
libraries were sequenced to generate 90 bp pair-end reads with at
least 303 average genome coverage per sample (Table S1). Filtered
reads were aligned to the reference genome (build GRCh37)
with the Burrows-Wheeler Aligner (BWA),27 allowing detection
of single-nucleotide variants (SNVs) and small insertions/deletions
(indels; <65 nucleotides).
Local realignment and quality recalibration were done with the
Genome Analysis Toolkit (GATK-1.4-30).28 Sequence Alignment/
Map tools (SAMtools)29 was used for removal of duplicated reads.
The effects (e.g., missense, nonsense, or frameshift mutations) and
classifications (e.g., in exonic, intronic, or intergenic regions) of
variants across the genome were annotated by ANNOVAR.30 The
number of SNVs and indels detected per sample is summarized
in Table S1.
Variant Confirmation
Primers were designed to span at least 100 bp upstream and down-
stream of the putative variant. For validation, 91 candidate muta-
tions in the whole genomes of one trio (2-1266) were selected
randomly, and all the 38 exonic de novo and ASD-relevant
variants were validated experimentally by Sanger sequencing, 2013
Figure 1. Detection and Classification of
Medically Relevant Genetic Variants
Rare SNV and indel variants were assessed
as putative etiologic factors in ASD. Sam-
ples were also run on high-resolution
microarray for CNV calling as indicated
in the Material and Methods. Dashed
arrows indicate variants not included
in downstream analyses. In addition to
applying random forests (RF) algorithms
and filtering methods, we used Sanger
sequencing to perform a manual assess-
ment of potential de novo variants anno-
tated by GATK.
aLow-quality variants were eliminated
with GATK’s filters.
bRare variants were defined as those not
found in dbSNP or the 1000 Genomes
Project. Each gene bearing rare deleterious
variants was classified as (1) a "known"
(also called "linked") ASD gene if it was pre-
viously identified to be involved in ASD,
according to lists developed by the Autism
Genome Project Consortium,3,7 (2) an
"unrecognized" ASD gene if it was not pre-
viously recognized to carry a loss-of-func-
tion mutation (nonsense, splice site, or
frameshift) and if it showed an ASD-related
phenotype, as reported in OMIM and/or
the MGI mouse knockout database, or (3)
a "candidate" ASD gene if it was affected
by a de novo deleterious variant. In
the case of rare inherited X-linked delete-
rious variants found in males, the same
gene also needed to be implicated in other
sequencing studies. Abbreviations are
as follows: GATK, Genome Analysis Tool-
kit; BWA, Burrows-Wheeler Aligner; and
segdup, segmental duplication(see below). Candidate regions from whole-blood-derived DNA
were amplified by PCR for all trios, as well as unaffected siblings
or other available family members.
De Novo SNV Detection
A potential de novo mutation was identified if there was a hetero-
zygous genotype in the offspring and homozygous reference geno-
types in both parents. First, we removed heterozygous calls in the
proband when more than 70% of reads were the reference call.
Next, we eliminated cases where a parent had more than 5% non-
reference reads that matched the proband’s heterozygous call. To
eliminate spurious calls that formed when the proband had a
homozygously deleted segment, we removed sites where the pro-
band’s read depth was <10% of the total parental read depth. We
refined furtherbyapplyingfiltersbasedon thegenotype likelihood,
denoted as a "phred-scale" (PL). We used PL ofR 30 for the geno-
types of the proband and both parents (i.e., the assigned genotype
is 1,000 timesmore likely tobe true than the alternativegenotypes).
Finally, we removed all the sites found in the dbSNP (dbSNP135),
given that common SNPs are unlikely to be de novo events.
We evaluated the approach by using the validation results of (1)
all genomic de novo SNVs in one family (2-1266) and (2) Sanger
sequencing of de novo exonic SNVs in all families (Table S2). For
genomic SNVs, 91 de novo SNVs were selected randomly for
validation by Sanger sequencing (86 PCR assays were designedThe Amerto detect 91 de novo SNVs); 64 of the 86 (74.4%) PCR assays
worked. Of the 64 putative de novo SNVs, 60 were confirmed as
being true positives (i.e., 94% validated). We detected 40 exonic
de novo SNVs, and 32 were confirmed as true positives (i.e., 80%
validated) (Table S2).
Refinement of de novo SNVs by theMachine-Learning
Method
To refine the de novo SNV detection approach, we used amachine-
learning-based classifier31 called forestDNM (RF-2). The method
was designed to distinguish de novo variants from false-positive
de novo mutations (DNMs) that arose from errors in sequencing,
alignment, or variant calling. We used a combination of thresh-
olds on site-quality metrics to determine which DNMs were likely
to be true positives. In order to facilitate the optimization process
and minimize bias, we adopted a data-driven approach for the
machine-learning process. First, we created a training data set by
using validation results from Sanger sequencing (including calls
validated as true and false positives) for all putative de novo
SNVs detected by the filter method in one trio (family 2-1266)
and for all exonic DNMs in 32 trios. Then, we trained the RF-2
to differentiate the validated de novo SNVs from the invalidated
putative de novo SNVs on the basis of a combination of associated
quality metrics. Finally, the trained RF-2 detected DNMs in the
remaining 31 trios.ican Journal of Human Genetics 93, 249–263, August 8, 2013 251
We detected 63 genomic de novo SNVs in family 2-1266 and 38
exonic de novomutations in all families by using this approach. In
family 2-1266, 60 of the 63 genomic de novo SNVs were those
found by the filter method (Table S2). For de novo exonic SNVs,
36 were confirmed as true positives (i.e., 95% validated). One
validated de novo exonic SNV from the filter method was missed
by RF-2.
De Novo Indel Detection
We applied similar filtering criteria for de novo indel detection: the
proband had to be heterozygous for the indel call, whereas the par-
ents both had to be homozygous reference at the same position.
The read depth at the variant position of each family member
was more than 103. Furthermore, the variant calls in the trio
data were selected with the following filters: a phred-scaled quality
score (QUAL) of more than 30; a QualByDepth (QD: variant con-
fidence from the QUAL field/unfiltered depth) of more than 10;
a HomopolymerRun (Hrun: Largest contiguous homopolymer
run of the variant allele in either direction on the reference) less
than 5; and a MappingQualityZero (MQ0: total count across all
samples that had reads with a mapping quality of zero) less
than 4. In addition to the essential variant-quality filters, the indel
call from the proband needed to be supported by at least 30% of
the reads, and there needed to be at least a 173 read depth.
Also, parents could have no reads with an indel at the same posi-
tion where an indel was detected in the proband. The filter matrix
was optimized by evaluating the performance on simulated trio
data containing de novo mutations generated by pIRS.32 On the
basis of the simulated trio data, the method showed 84% sensi-
tivity and a 5% false-detection rate.
Because de novo indels found in dbSNP and simple repeats were
prone to be false positives, we filtered out indels reported in
dbSNP135 and located in simple repeat regions (Table S3). We
designed PCR assays for 3 of the 4 indels identified in family
2-1266. Sanger sequencing confirmed that they were all true pos-
itives. We also validated the two de novo exonic indels and
confirmed that both were true positives (Table S3).
Manual Assessment of Potential De Novo Exonic
Variants
Because the automated de novo detection methods only take into
account de novo variants that are homozygous in parents and het-
erozygous in the proband, which is not applicable for variants on
the X chromosomes in males, we manually curated X-linked
hemizygous variants that occurred in male probands but were
not present at the same position in the X chromosome of their
respective mothers. This identified two additional de novo muta-
tions (in KAL1 and WWC3). In addition, we prioritized a list of
potential de novo exonic indels that were assigned by GATK
(23 in total) but were missed by the automated de novo detection
methods described above, and we validated them by using Sanger
sequencing. We thus confirmed one additional de novo indel
(found in MICALCL [MIM 612355]).
CNV Detection by Genomic Array and WGS
Although each of the 32 trios had been previously examined by
microarrays, we also tested them by using the CytoScan HD Array
(Affymetrix, Santa Clara, CA). These CNV calls provided an addi-
tional resource for comparison against the WGS data. We per-
formed CNV analysis by using four algorithms: Chromosome
Analysis Suite software (Affymetrix, Santa Clara, CA), iPattern,7252 The American Journal of Human Genetics 93, 249–263, August 8Nexus (BioDiscovery, CA), and Partek (Partek, MO). CNVs were
called when they were detected by at least two of the four algo-
rithms and spanned at least five or more consecutive array
probes.33
CNVnator was used for detection of CNVs from WGS as previ-
ously described.34 CNV calls with a p value < 0.05 and a size >1
kb were used, and calls with >50% of q0 (zero mapping quality)
reads within the CNV regions were removed (q0 filter). Rare
CNVs were defined as not present in the Database of Genomic Var-
iants (DGV)35. Putative de novo CNVs for each trio were detected
with the following criteria: (1) the normalized average RD signal in
the child was <1.4 (for deletions) or >2.6 (for duplications); and
(2) the normalized average RD signal in each parent was between
1.6 and 2.4. CNVs located in segmental duplications and repetitive
regions were removed.Variant Characterization
When assessing inherited variants, we removed those that are
common in the population (i.e., found in dbSNP135 or the 1000
Genomes Project). We determined X-linked or autosomal location
and the parent of origin by comparing to the genotypes of the par-
ents. All variants were annotated for their effects on the basis of
their sequence alterations. Rare (< 0.1% frequency) deleterious
variants including nonsense, splice site, frameshift, and damaging
missense mutations were selected for medical annotation and
family analysis. Variants of interest were verified by Sanger
sequencing for the trios and additional family members.
On average, there were 8,982 nonsynonymous SNVs per pro-
band (Table S4); we defined rare variants as those not found in
dbSNP135 or the 1000 Genomes Project,36 and there were 231
of such SNVs per proband (Table S4). We defined damaging
missense SNVs as those that both SIFT37 and PolyPhen-238
predicted to be damaging via the Variant Effect Predictor.39 There
were 40 rare damaging missense mutations, 75 rare splice-site
mutations, and six rare nonsense mutations per proband
(Table S4). We found 444 rare indels per proband; of these, 126
were denoted as rare frameshifts (Table S4). We examined the
frequency of all the ASD "clinically relevant" variants as identified
in the exome sequencing project (ESP6500) from NHLBI and the
Human Gene Mutation Database (Table S5).
To evaluate the performance of functional prediction by the
combination of SIFT and PolyPhen-2, we selected all the de novo
and inherited ASD-relevant missense mutations and performed
function prediction by using two other variant-prediction tools:
PANTHER40 and MutationTaster.41 Although all of these tools
have taken into account the conservation score, there are substan-
tial differences in their prediction strategies, in which their out-
comes were not necessarily concordant. However, the prediction
results we found in these variants were significantly correlated
(PANTHER p ¼ 0.003; MutationTaster p ¼ 0.0008).Medical Classification
We assessed the medical relevance of the detected genetic variants
to ASD by (1) predicting whether they were likely to have a delete-
rious effect on splicing of the gene or functional properties of the
protein product; (2) assessing the frequency of predicted dele-
terious variants in a population database (NHLBI GO Exome
Sequencing Project); (3) comparing these variants to known
ASD candidate genes;3,7 (4) looking at segregation in families
and comparing predicted mutations to disease genes in the
Online Mendelian Inheritance in Man (OMIM) database and (5), 2013
comparing predicted mutations to orthologous genes in the
Mouse Genome Informatics (MGI) phenotype database. We tested
X-inactivation as described by Allen et al.42Medical Annotation and Family Analysis
We examined the function of genes that carried rare deleterious
mutations in the documented neurodevelopmental/behavioral
phenotype of humans or mice. For humans, we used the human
phenotype ontology (HPO) resources and selected all genes anno-
tated for ‘‘behavioural/psychiatric abnormality’’ (HP:0000708)
and/or ‘‘cognitive impairment’’ (HP:0100543). We considered
genes with HPO phenotype annotation derived from OMIM
because only for these could we reliably infer the mode of inheri-
tance. For mice, we used the mammalian phenotype ontology
(MPO) annotations provided by Mouse Genome Informatics
(MGI). After removing quantitative trait loci (QTLs), complex
genotypes (i.e., requiring a combination of genotypes of different
genes), and phenotypes associated with transgenes, we selected
all genes annotated for ‘‘behavior/neurological phenotype’’
(HP:0000708) and/or ‘‘nervous system phenotype’’ (HP:0100543).
We also determined themode of inheritance for these genes. For
human phenotypes, we used the phenotype OMIM-number nota-
tion to determine the mode of inheritance: for OMIM IDs starting
with 1, we assumed an autosomal-dominant mode of inheritance;
for those starting with 2, we assumed an autosomal-recessive
mode of inheritance, and for those starting with 3, we assumed
an X-linkedmode of inheritance; OMIM identifiers corresponding
to official gene symbols were derived from the Bioconductor pack-
age org.Hs.egOMIM2EG, version 2.7.1, packaged on March 13,
2012. For mouse phenotypes, we inferred the mode of inheritance
on the basis of the genotype associated with the phenotype of
interest: (1) genes associated with the phenotypes of interest
through at least one autosomal-heterozygous genotype were
inferred to be dominant, (2) genes associated with the phenotypes
of interest only through an autosomal-homozygous genotype(s)
were inferred to be recessive, (3) genes with human orthologs
outside of the pseudo-autosomal regions on the X chromosome
were inferred to be X-linked. In the case of discordance between
mouse and human modes of inheritance (2.94% of the genes),
we retained only the human information. Medical annotation
results for each ASD-relevant variant are summarized in Table S5.
A summary of family analysis and assessment results is provided
in Table S6.Comparison between WGS and Whole-Exome
Sequencing
We selected ten whole-genome samples (from five males and five
females) from six families; we sampled probands as well as
mothers and fathers, and average autosome depth per sample
ranged from 333 to 393 (the average across samples was 35.63,
which is very close to the overall average of 35.73). We also
selected ten whole-exome samples (from five males and five
females), sequenced with HiSeq 2000 and the SureSelect capture
kit (SSV4) (Agilent Technologies, Santa Clara, CA), that were not
from the ASD cohort, and we used an analysis pipeline (prepro-
cessing, alignment) similar to that used for the whole genome.
The average autosome depth per sample of whole-exome samples
ranged from 78.33 to 144.33 (average across samples: 115.93).
Read depth was calculated for all exons according to the hg19
RefSeq June 14, 2012 version; the longest transcript was consid-
ered for each gene. For each exon, we calculated the averageThe Amersequencing depth for the entire exon as well as for five genomic
intervals overlapping the exon, as follows: (1) 10 intronic bp
upstream of the start of the exon (labeled ‘‘50 splice’’); (2) 10 exonic
bp downstream from the start of the exon (labeled ‘‘start’’); (3)
from 11 bp downstream of the exon-start to 11 bp upstream of
the exon end (labeled ‘‘middle’’); (4) 10 exonic bp upstream of
the end of the exon (labeled ‘‘end’’), and (5) 10 intronic bp down-
stream from the end of the exon (labeled ‘‘30 splice’’).
We also analyzed the SSV4 capture regions and the percent over-
lap with the coding sequence. We reported the coverage statistics
for known ASD risk genes on the basis of the number of exons that
had insufficient (d < 53) or low (53% d < 103) coverage or that
were not on the exome capture target (Figure S2). Coding exons
were defined as 100% overlapping the CDS; all other exons were
considered to be noncoding. To assess depth distribution, we first
calculated the average depth across exome and whole-genome
samples and then plotted the number of coding and noncoding
exons whose depth was equal to or greater than a given threshold
(53, 103, 203); coding exons were defined as those that were
100% overlapping with the CDS, and all other exons were consid-
ered to be noncoding. This analysis was done for all chromosomes
together, as well as for the X chromosome alone. We also gener-
ated a segmented distribution curve, resembling a density curve,
based on the number of exons within 10 depth unit bins
(e.g., 5:5, 5:15, .). Keeping male and female samples separate,
we generated a more detailed bar plot to display the number
of coding and noncoding exon intervals for the same depth
thresholds (Figure S2).Results
Genetic Variants in Whole-Genome Sequence
Thirty-two trio families comprising a child with ASD
(index case or proband) and both biological parents were
selected for WGS. Our primary criteria for selection were
that the index case fulfilled a formal diagnosis of ASD
according to gold-standard tests and our previous studies,
that no member of the trio carried a known pathogenic
CNV,7,20,26,43,44 and that all trio members had blood-
derived genomic DNA available. Otherwise, the families
were randomly selected from a larger research cohort of
more than 180 families of children with ASD, for which
similar criteria were met (The Autism Simplex Collection).
Beyond the trio, in many cases additional siblings and rel-
atives (with varying levels of phenotype data) were also
available for examination (Figure 2 and Table S6).
The average coverage relative to the human genome
reference sequence was 99.8%, and average sequence
depth was 38.43 (Table S1). We detected an average of
3,210,237 SNVs and 804,635 indels per genome. Of these,
an average of 19,241 SNVs and 510 indels were in exonic
regions. The concordance of SNVs between WGS and
microarray calls was high and ranged from 99.1% to
99.9% per sample.45 The overall validation rate for indels
was not determined but was expected to be low, as previ-
ously reported.46 In ASD probands, there were 8,982 non-
synonymous SNVs (missense and nonsense mutations)
and splice-site mutations and 444 indels per individual
(Table S4); 231 SNVs and 328 indels, on average, had notican Journal of Human Genetics 93, 249–263, August 8, 2013 253
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A B Figure 2. Correlation between Number
of De Novo Mutations and Parental Ages
The total number of de novo mutations
(DNMs) in the probandwas plotted against
the age of (A) the father and (B) the
mother. The number of mutations in-
creases with the age of the father (p ¼
0.0045) at a rate of 1.5 de novo mutations
per year (slope).been identified previously. As in other studies, herein we
use the term ‘‘mutation’’ to describe rare variants (defined
as those not found in the dbSNP or 1000 Genomes Project)
that were predicted to be deleterious (loss-of-function and
predicted damaging missense) by DNA sequence analysis
(Figure 1). 10–13,31,47–49
We used the program CNVnator and called an average of
5,705CNVs per individual from theWGSdata; this number
is 100 timesmore than thenumber ofCNVs detected by the
CytoScan HD microarray (which detected 45 CNVs per
individual) (Figure S3A). This is in part due to the limited
probe density for smaller CNVs (e.g., CNV size < 10 kb)
in the microarray platform (Figure S3B). However, when
restricted to the regions where microarray has sufficient
coverage (more than 5 probes in > 10 kb), we found that
CNVnator has a specificity of only 12% and a sensitivity
of 75% (Figures S3C and S3D). Despite the suboptimal
CNVdetection performance in particular for smaller unbal-
anced changes,50 we analyzed all available data and
confirmed that there was no obvious rare exonic CNV in
the known pathogenic regions.
De Novo Mutations
Detection of de novo mutations (mutations presumably
arising in a parental germline) represents an effective
approach to identifying genes linked to ASD.10–13 Using a
systemic approach to identify de novo variants (Figure 1),
we detected 2,097 de novo SNVs (65.5 per individual;
Table S2) and 164 de novo indels (5.1 per individual;
Table S3). There were 42 de novo variants detected in
exons (1.3 per individual) (Table S5); of these variants, 34
were nonsynonymous, and five were synonymous (ratio
6.8, which exceeds the ratio of 1 seen across a single
genome51). There were three nonsense and 31 missense
mutations. Functional analysis with both PolyPhen-2
and SIFT predicted that 13 of the 31 missense mutations
would be deleterious. The three de novo indels detected
were all predicted to cause frameshift mutations in the
affected genes. Consistent with previous studies,31,49 we
found that the number of de novo mutations was signifi-
cantly correlated with paternal age (p < 0.005), but not
with maternal age (p ¼ 0.37) (Figure 2).254 The American Journal of Human Genetics 93, 249–263, August 8, 2013Of these 32 probands, 15 (47%)
were found to carry at least one de
novo deleterious mutation (Tables S5
and S6). By evaluating the severity
and medical relevance of these mu-tations (Figure 1), we determined that, in six of 32 (19%)
probands, these de novo events possibly contributed
to clinical symptoms (Figures 3A–3F; Table1). In family
2-1186, the proband (II-1 in Figure 3A) had a de
novo nonsense mutation (c.219T>A [p.Tyr73*]) that dis-
rupts the VIP (MIM 192320; RefSeq accession number
NM_003381.3) on chromosome 6. The proband has
average intelligence by standardized testing and a clinical
diagnosis of Asperger syndrome. The younger male sibling
of the proband (I-2 in Figure 3A) also carried the mutation.
Upon revisiting this individual’s records, the referring clini-
cian (without knowledge of the molecular result) indicated
that he had subclinical features of ASD and needed to be
called back for a full assessment (clinical details are given
in Table S6). He presented with expressive language
delay, above-average receptive vocabulary, and a history
of ‘‘clumsiness.’’ The mutation was not found in either
parent, which might reflect gonadal mosaicism in one of
them. VIP is involved in circadian rhythm, and mutant
mice exhibit social behavioral and cognitive deficits.52,53
In family 2-1305, the proband (II-1 in Figure 3B) had a
nonsense de novo mutation (c.1195C>T [p.Gln399*]) in
CAPRIN1 (MIM 601178; RefSeq NM_005898.4), which
is functionally related to the fragile X protein (FMRP).54
According to medical history, this proband had fetal
distress and a respiratory problem. These features have
similarly been seen in Caprin1-null mice55 (Table S7). In
family 2-1337, the proband with intellectual disability
(II-2 in Figure 3C) had a de novo 32 bp deletion (c.1317–
1348del [p.440–450del]) that causes a frameshift in an
ASD-linked gene, SCN2A (RefSeq NM_001040143.1),
which encodes the type II alpha subunit of a voltage-gated
sodium channel.3,10,13 A female sibling with ASD but
normal IQ did not have this mutation, suggesting that
the phenotype associated with this mutation might be
intellectual disability rather than ASD per se. On the other
hand, Sanders et al. reported that two ASD probands from
the Simons Simplex Collection had de novo loss-of-
function mutations in SCN2A, but information about
IQwas not provided.10 Rauch et al. reported three probands
with severe intellectual disability and de novo mutations
in SCN2A; two of these individuals had autistic features.56
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Figure 3. Pedigrees of Families with ASD-Relevant Genetic Variants
(A–F) Families with de novo deleterious variants as potential causal events.
(G–P) Families with inherited deleterious variants as potential causes of ASD (the sibling in Family A was also found to be a mutation
carrier, suggesting gonadal mosaicism).
The de novo or inherited variant alleles are shown below each family member. ‘‘þ’’ indicates the allele containing the reference (presum-
ably wild-type) sequence (‘‘þ/þ’’ for genes on the autosomal chromosome or the X chromosome in female; ‘‘þ’’ for genes on the X chro-
mosome inmale). Males are denoted by squares and females by circles. Symbols with no inside number indicate that no DNA sample was
available for testing. Black symbols indicate individuals diagnosed with ASD. Individual 2-1269-03 (dark gray symbol) was diagnosed
with Asperger disorder in adulthood. Symbols filled in light gray (2-1186-04 [A; II-2] and 2-1116-04 [M; II-1]) denote individuals with
subclinical features of ASD. As discussed in the Results, individual 2-1269-04 (G; III-2) was also reported by the parents to exhibit
autistic-like behavior, and a full ASD evaluation is ongoing. Open symbols denote unaffected individuals, according to currently avail-
able information, but status for some may change upon retrospective evaluation. Arrows indicate ASD probands in each family.A possible scenario in our family is that the SCN2A muta-
tion exerts a greater effect on overall intellectual function
and that the ASD phenotype is incompletely penetrant.
Alternatively, multiple incompletely penetrant genetic
variants might contribute to autism in these siblings,
which would be consistent with the often multigenic
nature of familial ASD and has been observed in other
families.22 The proband in family 2-1370 (II-2 in
Figure 3D) had a de novo 1 bp insertion (c.1194dup
[p.Ser399Glufs*10]) in USP54 (RefSeq NM_152586.3),
which codes for ubiquitin peptidase in the brain.57 There
is no other supporting genetic evidence of a role for this
gene in ASD, so its relevance remains to be determined.
The male proband in family 2-1303 (II-1 in Figure 3E),
diagnosed with ASD and borderline intellect at age
14 years, was found to have a nonsense de novo muta-
tion (c.1267C>T [p.Arg423*]) in the X-linked KAL1
(MIM 300836; RefSeq NM_000216.2), associated with Kall-
mann syndrome (MIM 308700). The boy was clinicallyThe Amerdiagnosed with Kallmann syndrome prior to WGS (but
after ASD diagnosis) because of hypogonadism and
anosmia. Therefore, in this case we are confident that the
p.Arg423* substitution in KAL1 causes his Kallmann syn-
drome, and possibly contributes to his ASD on the basis
of the protein’s role in neural development.58,59 However,
we are not aware of previous reports of autistic features
inKAL1-mutation-positive individuals with Kallmann syn-
drome, so this is speculative pending further study. In
family 2-1276, a de novo frameshift insertion (c.1193-
1194insA [p.Ser399Leufs*10]) in MICALCL (MIM 612355;
RefSeq NM_032867.2) was identified in the proband (II-1
in Figure 3F). This gene is largely uncharacterized, but
exome sequencing had revealed a de novo missense muta-
tion in an unrelated individual with ASD.12 Proband
2-1276-03 (II-1 in Figure 3F) also has a de novo deleterious
missense mutation (c.1903C>T [p.Arg635Trp]) in the DNA
methyltransferase, encoded by DNMT3A (MIM 602769;
RefSeq NM_175629.2).ican Journal of Human Genetics 93, 249–263, August 8, 2013 255
Table 1. Summary of ASDa-Associated Genes Found with Mutations in this Study
Known Genes Unrecognized Genes Candidate Genes
X-Linked Autosomal X-Linked Autosomal X-Linked Autosomal
Missense
(damaging)
AFF2, ARHGEF6,
DMD
CACNA1C, CHD7,
EHMT1, SATB2, SCN2A,
NRXN1
- - BCORL1, WWC3,b
ZC3H12B
ARID5A,b DNMT3A,b
KIAA0284b
Nonsense - - KAL1b,c CAPRIN1,b,d VIPb,d - -
Frameshift - SCN2Ab - - - USP54,b MICALCLb
Splice Site - - - KCNQ2c - -
aMutations of interest were found in 16 families, of which five families carried more than one mutation. Deleterious mutations were found in four unrecognized
genes in four families, in nine known genes in ten families, and in eight candidate genes in seven families.
bGenes with de novo mutations in the proband.
cSupported by human phenotype from OMIM.
dSupported by mouse phenotype from MGI.Inherited Mutations in X-Linked Genes
Given the strong male-to-female gender bias in ASD60 and
recent progress in finding X-linked forms of ASD and
intellectual disability,61–63 we sought to detect additional
X-linked mutations that males had inherited from their
unaffected mothers. We identified 12 rare X-linked delete-
rious variants among eight male ASD probands and their
mothers. Of these, five mutations (in four families)
affected previously identified ASD candidate genes (Fig-
ures 3G–3J). In family 2-1269 (Figure 3G), a rare missense
mutation (c.2662G>A [p.Val888Ile]) was found in AFF2
(MIM 300806; RefSeq NM 001170628.1), mutations in
which cause fragile X E syndrome (MIM 309548).64 The
male proband in family 2-1353 (II-2 in Figure 3H) has
missense mutations (c.806G>T [p.Arg269Ile]; c.953G>A
[p.Arg318Gln]) in ARHGEF6 (MIM 300267; RefSeq
NM_004840.2) and ZC3H12B (MIM 300889; RefSeq NM
001010888.3); the former gene is implicated in X-linked
intellectual disability (MIM 300436),3 and the latter has
been found to be mutated in another unrelated individual
with ASD.11 The male proband of family 2-1330 (III-1 in
Figure 3I) inherited an X-linked missense mutation
(c.5477G>T [p.Arg1826Ile]) in DMD (MIM 300377;
RefSeq NM_004009.3), mutations in which cause dystro-
phinopathies Duchenne and Becker muscular dystrophy
(DMD and BMD; MIM 310200 and 300376, respectively).
Previous reports have suggested an increased incidence of
ASDs in boys with DMD.3,21 The individual in question is
now 14 years old and does not show obvious signs of
muscular dystrophy, but he will need to be assessed
further. In addition, a de novo missense mutation
(c.2819G>A [p.Arg940Gln]) was identified in the unchar-
acterized X-linked gene WWC3 (NM_015691.3). Finally,
we found a rare missense BCORL1 (MIM 300688; RefSeq
NM_021946.4) mutation (c.3269G>C [p.Arg1090Pro])
that was predicted to be damaging in the male ASD-
affected proband of family 2-1375 (II-2 in Figure 3J). A
de novo missense mutation (c.2390G>A [p.Cys797Tyr])
of the same gene was also reported in another unrelated
individual with ASD.10256 The American Journal of Human Genetics 93, 249–263, August 8Inherited Dominant Mutations in Autosomal Genes
Heritability estimates strongly support a significant
role for autosomal inherited factors,18,23,24 but genome-
wide studies of inherited autosomal mutations in ASD
have so far been limited to the model of recessive
inheritance;63,65,66 some mutations have been identi-
fied.19,63,65,66 Given the expanding number of rare variants
in the human population,67–69 we also explored the possi-
bility of accumulation of deleterious variants in the known
ASD-linked genes with haploinsufficiency, in addition to
the recessive ones in these 32 families.
We found that seven out of 32 (22%) families carried rare
mutations that are predicted to have deleterious effects,
that have been associated with ASD, and that segregate
in an autosomal-dominant manner (Figures 3G and
3K–3P). Family 2-1269 (Figure 3G), described above with
regard to the X-linked variant in AFF2, also carried a rare
paternally inherited splice-site mutation (c.1247þ1G>A)
in KCNQ2 (MIM 602235; RefSeq NM_172109.1). Defects
in KCNQ2 are implicated in benign familial neonatal sei-
zures type 1 (MIM 121200).70 Microdeletions encompass-
ing KCNQ2 have been reported in ASD cases.71 Mutations
in this gene and its other gene family member, KCNQ3
(MIM 602232), have also recently been associated with
intellectual disability in a few families.56,72 Medical history
indicates that seizures were present in both the proband
(III-1) and father (II-1) during early infancy.4 In fact, as a
result of a follow-up interview motivated by our genetic
findings, the female sibling, who carried the KCNQ2muta-
tion, was also reported by parents to exhibit autistic-
like behavior, and she is now undergoing formal exam-
ination. In family 2-1272, a CHD7 (MIM 608892;
RefSeq NM 017780.3) missense mutation (c.3566G>A
[p.Arg1189His]) that is predicted to be damaging was
found in the proband (III-1 in Figure 3K), and although
this alteration was inherited from his father (II-1), it was
not observed in biological grandparents (I-1 and I-2). Mu-
tations of CHD7 are associated with CHARGE syndrome
(MIM 214800), a developmental condition in which
27.5%–42% of the affected individuals are reported to, 2013
A B
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Figure 4. Sequencing Coverage in
Exonic Regions
(A) Comparison of sequencing depth in
autosomal exonic regions.
(B) Comparison of sequencing read distri-
bution in autosomal exonic regions.
(C) Comparison of sequencing depth in X
chromosome exonic regions.
(D) Comparison of sequencing read distri-
bution in X chromosome exonic regions.
WGS captured (A) 10.8% more annotated
exons (2.7% more coding) in autosomes
and (C) 17.5% more annotated exons
(5.7% more coding) in the X chromosome
with coverage >5x than WES did. WGS
also showed a more uniform capturing of
coding regions than WES (B and D).have autistic-like behavior.73,74 The proband carrying the
mutation has some symptoms, such as sleep apnea and
frequent ear infections,75,76 that can be found in CHARGE
syndrome, but determining whether he fits full clinical
criteria for the diagnosis (Table S7) will require assessment
by a clinical geneticist. Fewer clinical data are available for
the father, who should also be assessed for CHARGE syn-
drome and/or ASD features.
The proband (III-3 in Figure 3G) and two unaffected
sisters (III-1 and III-2 in Figure 3G) of family 2-1291 in-
herited, from the non-ASD mother, a rare p.Arg28Cys
missense substitution (c.82C>T) in SCN2A, which was
also mutated in family 2-1337 and has been found in other
recent studies to be involved in ASD, as well as intellectual
disability.10,13,48,56 The ASD proband of family 2-1116 (II-2
in Figure 3M) and one brother (II-1 in Figure 3M) inherited
a rare missense mutation (c.2653C>T [p.His885Tyr]) in
NRXN1 (MIM 600565; RefSeq NM_001135659.1) from
their father (I-1 in Figure 3M). Although the brother
has not been diagnosed with ASD, he has learning
disability. Mutations in CACNA1C (MIM 114205; RefSeq
NM_001129842.1) can cause ASD-associated Timothy
syndrome (MIM 601005), and a rare missense mutation
(c.4565G>A [p.Arg1522Gln) of this gene in family 2-1244
is carried by the proband (II-1 in Figure 3N) and his unaf-
fected father (I-1 in Figure 3N) and brother (II-2 in
Figure 3N). The familial mutation is not the same as
that typically associated with Timothy syndrome, so it is
unclear whether the family is at risk for arrhythmias (MIM
600919) that are typically associated with this condition.
The proband in family 2-1352 (III-2 in Figure 3O)
inherited from his mother (II-2 in Figure 3O) rare
missensemutations (c.3295C>G [p.Pro1099Ala]; c.916G>AThe American Journal of Human G[p.Val306Met]) in both EHMT1 (MIM
607001; RefSeq NM_024757.4) and X-
linked NLGN3 (MIM 300336; RefSeq
NM_001166660.1) (although the latter
alteration is predicted to be benign
by bioinformatic analysis). Finally,
the proband in family 2-1334 (III-2in Figure 3P) inherited a rare missense mutation
(c.1963C>T [p.Pro655Ser]) in SATB2 (MIM 608148; RefSeq
NM_015265.3) from his unaffected father (II-1 in
Figure 3P) and grandfather (I-1 in Figure 3P). No biallelic
mutationswere identified inASDcandidate genespreviously
shown to demonstrate autosomal-recessive inheritance
patterns3,63,77.
Coverage of Coding Exons by WGS
To evaluate the performance of variant detection by WGS,
we compared the sequence coverage in the exonic regions
betweenWGS and whole-exome sequencing (WES). In the
autosomal regions, we found that WGS covered at least
10.8% more annotated exons than WES did (Figure 4).
Furthermore, 9.2% (11/119) of ASD-linked genes have at
least one exon untargeted by the most widely used capture
kit currently available for exome sequencing (Figure S4; see
also the Discussion). A more detailed comparison between
the two technologies’ coverage in the coding regions
showed that WGS captured 2.7% more annotated coding
exons with coverage sufficient for variant calling (>5x)
than did WES (Figure 4). The coverage difference was
even more prominent for the X chromosome and gene
splice sites (Figure S2), the former of which carries a dispro-
portionate number of ASD susceptibility genes.Discussion
Multiple lines of evidence demonstrate the importance of
complex genetic factors in ASD (chromosomal abnormal-
ities, CNVs, indels, SNVs).5,6 At the same time, careful clin-
ical characterization has revealed that ASD is extremelyenetics 93, 249–263, August 8, 2013 257
heterogeneous, in that it ranges from milder Asperger dis-
order to more complex forms associated with profound
intellectual disability, epilepsy and other medical prob-
lems.1,3 As a pilot study, we used WGS in a group of fam-
ilies with at least one child affected by ASD to provide
more comprehensive detection of the wide-ranging
genetic variants that might contribute to ASD risk. We, as
others have, sought de novo variants,10–13,31,49 but
given the well-established role of inherited factors in
ASD,18,23,24 we also considered rare autosomal and
X-linked inherited variants in families. Following this
design, we ascertained potentially significant variants in
16 of 32 families (50%); this potential significance was
either because the genes involved have an established asso-
ciation with clinical syndromes found among individuals
with ASD or because they are linked to ASD and/or related
disabilities, such as intellectual disability, or medical
co-morbidities, such as seizures. Further investigation of
the clinical relevance of these variants is ongoing. Some
of the detected mutations could reasonably be considered
pathogenic and/or have possible implications for clinical
management or genetic counseling for the proband or
familymembers. For othermutations, their role in the con-
dition needs to be closely followed in themedical literature
(Table S7; Figure 3). Such putative mutations were identi-
fied in nine genes previously linked to ASD, as well as in
four unrecognized and eight candidate ASD risk genes
(defined in Figure 1 legend) in these 16 families (some car-
ried more than one mutation) (Table 1).
Thirteen out of 32 (41%) probands (and some family
members) would be prioritized for comprehensive clinical
assessment on the basis of the presence of the mutation
and the predicted functional impact of the mutation(s)
andgene(s) (Table S7). These include all probandswhocarry
mutations in known and unrecognized ASD-linked genes
(Table 1). The c.5477G>T mutation in DMD in a boy with
ASD (family 2-1330; III-1 in Figure 3I) indicated that he
should be examined for dystrophinopathy, which is associ-
ated with progressive muscle weakness and cardiomyopa-
thy. In family 2-1303, the ASD proband (II-1 in Figure 3E)
later received a diagnosis of Kallmann syndrome (mirror
movements, microphallus, and unilateral renal agenesis
[MIM 308700]).78 WGS detected a de novo mutation in
KAL1, an X-linked gene that accounts for ~10% of cases of
Kallmann syndrome (see GeneReviews entry in Web
Resources), and after genetic confirmation of the disorder,
managementcan includehormone treatment to initiatepu-
berty. Detection of a c.3566G>A mutation in CHD7 in the
proband (III-1 in Figure 3K) and father (II-1 in Figure 3K)
in family 2-1272 indicates that they should be assessed for
CHARGE syndrome.75,76 CHD7 mutations are also found
in rare cases of Kallmann syndrome, which, like CHARGE
syndrome, can feature sensory impairment and hypogo-
nadism.79 In families 2-1337, 2-1291, 2-1244, and 2-1352,
carriers of mutations of SCN2A, CACNA1C, and EHMT1
should be assessed for features of epilepsy, Timothy syn-
drome, andKleefstra syndrome (MIM610253), respectively.258 The American Journal of Human Genetics 93, 249–263, August 8These individuals, along with the sibling who was a carrier
of the VIP mutation and reportedly exhibited symptoms
of ASD, should also undergo full assessment for ASD and/
or related neurodevelopmental disorders.
In the future, results of WGS might allow earlier diag-
nosis of ASD, especially in siblings, for whom recurrence
rates are approximately 18%.80 For families of probands
with de novo mutations in genes such as SCN2A and
CAPRIN1, recurrence risk might be similar to that of the
general population (but note that, as in family 2-1186,
germline mosaicism can confound estimates).81 The pres-
ence of rare inherited variants in ASD candidate genes
such as CACNA1C, CHD7, and KCNQ2, as well as X-linked
mutations in genes such as AFF2 and ARGEF6 in males,
might confer increased risk that would lead to a recom-
mendation of increased developmental monitoring to
allow earlier identification. The average age of ASD diag-
nosis in this group of 16 families was 4.4 years old; for
some of these families mentioned above, the genetic find-
ings could have informed diagnosis, thus shortening the
diagnostic path and allowing children to benefitmore fully
from early interventions.82 The X-linked gene mutations
also help to explain the male gender bias observed in ASD.
The reported genetic variants also highlight potential
molecular targets for pharmacologic manipulation and
open the way for personalized therapeutics in ASD. For
example, personal mutations in CAPRIN1, AFF2, and
SCN2A (families 2-1305, 2-1337, 2-1269, and 2-1291)
identify carriers as potential candidates for drug trials,
involving allosteric modulators of GABA receptors, which
have ameliorated autism-like symptoms in mice.83–85
Mutation of KCNQ2 in family 2-1269 identifies a candidate
pathway for treatment by Kv7 channel openers, such as re-
tigabine.86 The VIP variant highlights a potential drug
target pathway, in that the family of receptors (VPAC1
and VPAC2) that mediate its effects, along with related
peptides such as pituitary adenylate cyclase-activating
polypeptide (PACAP), are considered to be drug targets in
neurodegenerative and inflammatory diseases.87
With respect to sequencing, we detected a higher rate of
de novo mutations than was previously found in ASD
exome projects,10–13 which could be due to the more uni-
form capturing that WGS affords of the entire coding
regions (Figure 4). Although paternal age difference
between studies might contribute to the increase in yield,
we did not find a significant difference between the
paternal age in our study and that in others10–13 (Figure 2;
average age 34, range: 27–44). We also note that six out of
56 (11%) of the de novo and clinically relevant mutations,
including the mutations in VIP and KCNQ2, found in this
study would not have been captured by exome sequencing
(Table S5), although this might depend on the capturing
method used and the coverage achieved.WGS also demon-
strated a more uniform coverage; the majority of the exon
samples had a coverage of ~303 (ranging from 0 to ~50x),
whereas WES had a distribution of coverage ranging from
0 to ~2003 (Figure 4B). A similar pattern of coverage, 2013
difference was observed on the X chromosome (Figures 4C
and 4D), but there was an even higher extent of difference:
at least 17.5% more annotated exons (5.7% more coding)
were covered byWGS than byWES. Such a coverage differ-
ence was even more pronounced when regions such as
gene splice sites were considered (Figure S2). Supporting
our findings, a recent study reported that WES could not
detect 11% of the variants detected by WGS.88 Although
there are also WES-specific variants that could be missed
by WGS, the number was less significant.89 Of course,
WGS also covers the entire genome. However, calling
CNVs from WGS remains a challenge.90 Using a read-
depth-based approach for CNV detection, we found that
as many as 88% of the calls could be false positives
(Figure S3). As we test other existing and improved annota-
tion algorithms, the as-yet-undiscovered indels and CNVs
in both genic and nongenic intervals will also become
available for genotype and phenotype studies in these
and other ASD families.
We have presented a comprehensive analysis of the
genomes of individuals with ASD by usingWGS. Although
limited by the small sample size (32 unrelated trios), we
have attempted to fully utilize the public databases on
allelic frequency and functional information to delineate
the underlying genetic variants contributing to ASD risk.
The genetic variants reported in this study are extremely
rare because they are not present in more than thousands
of non-ASD individuals from public databases. Because
these mutations were specific to the families, genotype-
phenotype correlation could only be performed in the
context of the corresponding families, particularly for the
inherited mutations. All autosomally inherited deleterious
mutations we present here reside in ASD candidate genes
whose established mechanism of action is likely to be hap-
loinsufficiency. Thus, they were likely to be expressed in a
dominant manner, in some cases possibly with incomplete
penetrance and/or variable expressivity. Although each
individual carries hundreds of deleterious variants, many
have been previously documented to be recessive and
therefore are not known to be pathogenic. A recent study
of rare deleterious variants in the whole genomes of 179
individuals revealed that very few known pathogenic vari-
ants were found in genes associated with dominant disor-
ders after very stringent filters were applied, and the asso-
ciated phenotypes were either late onset or no overt
disease,47 suggesting that rare deleterious mutations found
in genes associated with known dominant disorders are
rare. Indeed, some families in our study showed a correla-
tion of phenotype with the associated known outcome
of the variants (e.g., family 2-1269, showing the KCNQ2
mutation, among other families in Table S7), but the
reason that some carriers were unaffected remains to be
determined. Further population-genetic and functional
studies of the variants, and reassessments of the carriers,
are needed to address this issue.
In conclusion, our study provides evidence that
WGS data can aid in the detection and clinical evalua-The Amertion of individuals with ASD and their families. The diag-
nostic yield and clinical utility should increase as more
undetected structural genetic variants are discovered
and characterized and as additional individuals with ASD
are studied. Although the cost per sample for WGS is
currently ~2.5 times more than that for WES, these
results suggest that more comprehensive coverage of the
exome and noncoding regions offers higher yield in
detected mutations which, in some cases, have significant
diagnostic and clinical utility for individuals with ASD and
their families. As more samples are analyzed by WGS, a
thorough health-technology assessment study will need
to be performed. Importantly, our genomic data reinforce
the growing number of observations that significant clin-
ical and genetic heterogeneity and pleiotropy exist in
ASD. WGS offers one tool that can help to advance the un-
derstanding of the genetic architecture of ASD.Supplemental Data
Supplemental data include four figures and seven tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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